A Phase 4 interventional study of rituximab [MabThera/Rituxan] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 4 sites in Tunisia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-16.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 103rd largest by enrollment, is one of 7 that started in 2008, is one of 38 in phase 4, and was the 42nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 128th largest by enrollment of the 141 interventional ones that give a count, is one of 11 that started in 2008, is one of 28 in phase 4, and was the 69th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and background methotrexate (10-25mg po or sc weekly). After the initial study period of 24 weeks, eligible patients may receive up to 3 re-treatments with MabThera. The anticipated time on study treatment is 1-2 years and target sample size is \<50
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: methotrexate · Drug: methylprednisolone
Drug page: Rituximab
1000 mg iv infusion on days 1 and 15
10-25 mg weekly (oral or parenteral)
100 mg iv prior to each rituximab infusion
Number of Participants Reporting Adverse Events (AEs)
Time frame: Days 1 and 15, every 8 weeks up to Week 24 and and then every 3 months up to 18 months for a total of 104 weeks
Percentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], participant's global assessment of disease activity \[visual analog scale: \[VAS\] 0 equals (=) no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to 10. Scores less than (\<) 2.6 indicate best disease control and scores greater than or equal to (≥) 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. The average improvement at each visit to the group score is equal to the formula (Previous DAS28 minus \[-\] current DAS 28)/ Previous DAS 28 x 100. Negative percentages indicate that the participant has worsened in comparison to last evaluation, and positive percentages indicate improvement of its DAS28 score and correlated with a bettering of clinical situation.
Time frame: Baseline and Week 24
Percentage of Participants Whose DAS28 Improved by >1.2 at Week 24
The DAS28 score is a measure of the participant's disease activity calculated using the TJC \[28 joints\], SJC \[28 joints\], participant's global assessment of disease activity \[VAS: 0 = no disease activity to 100 = maximum disease activity\] and the ESR for a total possible score of 0 to 10. Scores \< 2.6 indicate best disease control and scores ≥ 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. An improvement of \>1.2 was considered to be clinically significant improvement.
Time frame: Baseline and Week 24
Change in Bone Density (in Participants Untreated With Bisphosphonates)
Bone mineral density test was performed using x-ray radiation and the values of bone density were provided directly by the apparatus as grams per square centimeter (g/cm\^2) . T-score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as the participant. A T-score with above -1 is normal bone density level. A T-score between -1 and -2.5 means that the bone density is below normal and it might be a sign of an osteopenia and may also lead into osteoporosis. A T-score below -2.5 indicates osteoporosis.
Time frame: Screening and Week 84
| Milestone | Rituximab |
|---|---|
| Started | 18 |
| Completed | 12 |
| Not completed | 6 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Treatment failure | 1 |
| number of participants | Rituximab |
|---|---|
| Participants who experienced an AE | 11 |
| Participants who experienced more than 1 AE | 7 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], participant's global assessment of disease activity \[visual analog scale: \[VAS\] 0 equals (=) no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to 10. Scores less than (\<) 2.6 indicate best disease control and scores greater than or equal to (≥) 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. The average improvement at each visit to the group score is equal to the formula (Previous DAS28 minus \[-\] current DAS 28)/ Previous DAS 28 x 100. Negative percentages indicate that the participant has worsened in comparison to last evaluation, and positive percentages indicate improvement of its DAS28 score and correlated with a bettering of clinical situation.
| percentage change from baseline | Rituximab |
|---|---|
| Percentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24 | -1.7 ± 49.4 |
The DAS28 score is a measure of the participant's disease activity calculated using the TJC \[28 joints\], SJC \[28 joints\], participant's global assessment of disease activity \[VAS: 0 = no disease activity to 100 = maximum disease activity\] and the ESR for a total possible score of 0 to 10. Scores \< 2.6 indicate best disease control and scores ≥ 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. An improvement of \>1.2 was considered to be clinically significant improvement.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants Whose DAS28 Improved by >1.2 at Week 24 | 75.0 |
Bone mineral density test was performed using x-ray radiation and the values of bone density were provided directly by the apparatus as grams per square centimeter (g/cm\^2) . T-score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as the participant. A T-score with above -1 is normal bone density level. A T-score between -1 and -2.5 means that the bone density is below normal and it might be a sign of an osteopenia and may also lead into osteoporosis. A T-score below -2.5 indicates osteoporosis.
| t-score | Rituximab |
|---|---|
| Screening | -1.82 |
| Week 84 | -1.6 |
Collected over AEs were recorded from the day of first infusion until the End of Study at 104 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab | — | 6/18 (33.3%) | 9/18 (50%) |
| Event | Rituximab |
|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/18 |
| Persistent thrombopeniaBlood and lymphatic system disorders | 1/18 |
| Rectal bleedingGastrointestinal disorders | 1/18 |
| Ventricular Extra systolebigeminyCardiac disorders | 1/18 |
| Severe infusion reactionInjury, poisoning and procedural complications | 1/18 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/18 |
| Event | Rituximab |
|---|---|
| HypertensionBlood and lymphatic system disorders | 2/18 |
| Blurred VisionEye disorders | 1/18 |
| HyperglycemiaEndocrine disorders | 1/18 |
| Multi-sensitive Streptococcus CystitisInfections and infestations | 1/18 |
| Keratitis SeccaSkin and subcutaneous tissue disorders | 1/18 |
| Red ThroatGeneral disorders | 1/18 |
| VertigoEar and labyrinth disorders | 1/18 |
| SomnolenceGeneral disorders | 1/18 |
| InfluenzaInfections and infestations | 1/18 |
| Muscular PainMusculoskeletal and connective tissue disorders | 1/18 |
Intent-to-Treat (ITT) population: All participants who received any part of an infusion have been included in the ITT analysis. Participants who prematurely withdrew from the study for any reason and for whom an assessment was not performed for whatever reason, were still included in the ITT analyses.
| Age, Continuous(years) | Rituximab |
|---|---|
| Mean | 53.4 ± 7.91 |
| Sex: Female, Male(Participants) | Rituximab |
|---|---|
| Female | 16 |
| Male | 2 |
Ran from Mar 2008 to primary completion in May 2012, 49 months.
Results were first posted in Mar 2015, 2 years 10 months after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 49 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate